San Francisco Startup Aims to Edit Embryo Genes, Igniting Ethical Debate

A new San Francisco-based startup, Preventive, founded this year, has announced intentions that have instantly made it the center of intense controversy. The company plans to scientifically prove that CRISPR gene-editing technology can be safely used to alter the DNA of human embryos to eliminate hereditary diseases.

Backed by tech titans like Sam Altman (OpenAI) and Brian Armstrong (Coinbase), the project immediately garnered significant attention. Preventive emphasizes that its mission is not to create “designer babies,” but to help couples with serious genetic diseases, such as cystic fibrosis, have a biologically healthy child.

However, the main obstacle remains a legal vacuum: US federal legislation prohibits clinical trials on gene-editing of embryos intended for birth. This forces the startup to seek opportunities for research abroad, particularly in the United Arab Emirates. These plans immediately brought to mind the case of Chinese scientist He Jiankui, who was sentenced to prison for conducting similar experiments.